share_log

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3: Initial statement of beneficial ownership of securities-Officer Banjak Marc

iBio Inc | 3:首次持股声明-高管 Banjak Marc
美股SEC公告 ·  2024/08/15 05:26

Moomoo AI 已提取核心信息

Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
2024年8月14日,ibio inc 首席法务官Marc Banjak向证券交易委员会提交了《有利益所有权证券的初始声明》。根据1934年证券交易法第16(a)条的规定,申报要求详细说明Banjak在公司中所持有的非衍生和衍生证券的直接所有权。其中的非衍生证券包括1,875股普通股,由RSUs(限制性股票单位)代表,每季度最多释放1/12,最后一批在2024年3月31日释放。此外,申报还概述了多个期权,其行权价格和行权时间不同,其中包括:800股股票行权价格为$170.4,600股股票行权价格为$141.2,3,000股股票行权价格为$6.92,29,000股股票行权价格为$1.72,55,000股股票行权价格为$1.88。这些期权的行权期限从2022年到2034年不等,而且还要视Banjak是否继续在ibio inc工作而定。
2024年8月14日,ibio inc 首席法务官Marc Banjak向证券交易委员会提交了《有利益所有权证券的初始声明》。根据1934年证券交易法第16(a)条的规定,申报要求详细说明Banjak在公司中所持有的非衍生和衍生证券的直接所有权。其中的非衍生证券包括1,875股普通股,由RSUs(限制性股票单位)代表,每季度最多释放1/12,最后一批在2024年3月31日释放。此外,申报还概述了多个期权,其行权价格和行权时间不同,其中包括:800股股票行权价格为$170.4,600股股票行权价格为$141.2,3,000股股票行权价格为$6.92,29,000股股票行权价格为$1.72,55,000股股票行权价格为$1.88。这些期权的行权期限从2022年到2034年不等,而且还要视Banjak是否继续在ibio inc工作而定。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息